Pfizer Total Assets 2010-2022 | PFE

Pfizer total assets from 2010 to 2022. Total assets can be defined as the sum of all assets on a company's balance sheet.
  • Pfizer total assets for the quarter ending June 30, 2022 were $195.290B, a 14.93% increase year-over-year.
  • Pfizer total assets for 2021 were $181.476B, a 17.67% increase from 2020.
  • Pfizer total assets for 2020 were $154.229B, a 7.97% decline from 2019.
  • Pfizer total assets for 2019 were $167.594B, a 5.13% increase from 2018.
Pfizer Annual Total Assets
(Millions of US $)
2021 $181,476
2020 $154,229
2019 $167,594
2018 $159,422
2017 $171,797
2016 $171,615
2015 $167,381
2014 $167,566
2013 $172,101
2012 $185,798
2011 $188,002
2010 $195,014
2009 $212,949
Pfizer Quarterly Total Assets
(Millions of US $)
2022-06-30 $195,290
2022-03-31 $183,841
2021-12-31 $181,476
2021-09-30 $179,188
2021-06-30 $169,920
2021-03-31 $158,818
2020-12-31 $154,229
2020-09-30 $178,983
2020-06-30 $177,934
2020-03-31 $166,336
2019-12-31 $167,594
2019-09-30 $170,446
2019-06-30 $156,199
2019-03-31 $155,421
2018-12-31 $159,422
2018-09-30 $167,838
2018-06-30 $164,980
2018-03-31 $164,612
2017-12-31 $171,797
2017-09-30 $172,151
2017-06-30 $168,558
2017-03-31 $168,784
2016-12-31 $171,615
2016-09-30 $178,430
2016-06-30 $170,658
2016-03-31 $162,929
2015-12-31 $167,381
2015-09-30 $170,867
2015-06-30 $160,878
2015-03-31 $160,640
2014-12-31 $167,566
2014-09-30 $171,362
2014-06-30 $172,612
2014-03-31 $171,808
2013-12-31 $172,101
2013-09-30 $175,521
2013-06-30 $179,335
2013-03-31 $187,398
2012-12-31 $185,798
2012-09-30 $182,603
2012-06-30 $182,842
2012-03-31 $185,683
2011-12-31 $188,002
2011-09-30 $196,132
2011-06-30 $195,899
2011-03-31 $194,956
2010-12-31 $195,014
2010-09-30 $191,415
2010-06-30 $191,071
2010-03-31 $195,113
2009-12-31 $212,949
2009-09-30 $141,294
2009-06-30 $139,339
2009-03-31 $122,932
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $245.989B $81.288B
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $435.655B 16.59
Eli Lilly (LLY) United States $292.179B 37.05
AbbVie (ABBV) United States $249.673B 10.61
Merck (MRK) United States $218.318B 11.40
Novo Nordisk (NVO) Denmark $215.616B 28.44
Novartis AG (NVS) Switzerland $165.082B 12.17